Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.
Open accessPreprint — published as 10.1038/s41467-021-25167-5
Abstract
Both natural infection with SARS-CoV-2 and immunization with vaccines induce protective immunity. However, the extent to which such immune responses protect against emerging variants is of increasing importance. Such variants of concern (VOC) include isolates of lineage B.1.1.7, first identified in the UK, and B.1.351, first identified in South Africa. Our data confirm that VOC, particularly those with substitutions at residues 484 and 417, escape neutralization by antibodies directed to the ACE2-binding Class 1 and the adjacent Class 2 epitopes but are susceptible to neutralization by the generally less potent antibodies directed to Class 3 and 4 epitopes on the flanks of the receptor-binding domain. To address the potential threat posed by VOC, we sampled a SARS-CoV-2 uninfected UK cohort recently vaccinated with BNT162b2 (Pfizer-BioNTech, two doses delivered 18-28 days apart), alongside a cohort sampled in the early convalescent stages after natural infection in the first wave of the pandemic in Spring 2020. We tested antibody and T cell responses against a reference isolate of the original circulating lineage, B, and the impact of sequence variation in the B.1.1.7 and B.1.351 VOC. Neutralization of the VOC compared to B isolate was reduced, and this was most evident for the B.1.351 isolate. This reduction in antibody neutralization was less marked in post-boost vaccine-induced responses compared to naturally induced immune responses and could be largely explained by the potency of the homotypic antibody response. After a single vaccination, which induced only modestly neutralizing homotypic antibody titres, neutralization against the VOC was completely abrogated in the majority of vaccinees. Importantly, high magnitude T cell responses were generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. These data indicate that VOC may evade protective neutralizing responses induced by prior infection, and to a lesser extent by immunization, particularly after a single vaccine dose, but the impact of the VOC on T cell responses appears less marked. The results emphasize the need to generate high potency immune responses through vaccination in order to provide protection against these and other emergent variants.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The AstraZeneca ChAdOx1 vaccine has been associated with a partial loss of neutralizing antibody activity against B.1.1.7 and a large loss of neutralizing activity against B.1.351.
“Concerning vaccination responses, the AstraZeneca ChAdOx1 vaccine has been associated with a partial loss of neutralizing antibody activity against B.1.1.715 and a large loss of neutralizing activity against B.1.351.26”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [15]
The impact of B.1.1.7 mutations on neutralizing antibody titers is moderate.
“In general, the impact of B.1.1.7 mutations on neutralizing antibody titers is moderate.15, 16, 17, 18,20,24”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [15]
Mutations in B.1.351 and P.1 variants are associated with the more pronounced loss of neutralizing capacity.
“In contrast, mutations in B.1.351 and P.1 variants are associated with the more pronounced loss of neutralizing capacity.15,16,22,23,25”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595 · see citing works
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · see citing works
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · see citing works
Self-citationDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works
Self-citationStarr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · see citing works
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · see citing works
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747 · see citing works
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504 · see citing works
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343 · see citing works
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257 · see citing works
Self-citationPeng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0782-6 · Cited by 1,179 · see citing works
Self-citationSARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · see citing works
Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068 · see citing works
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works
Wilkinson, T. M., Li, C. K. F., Chui, C. S. C., Huang, A. K. Y., Perkins, M., Liebner, J. C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2612 · Cited by 974 · see citing works
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 949 · see citing works
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · see citing works
Self-citationCellular immune correlates of protection against symptomatic pandemic influenza
Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T., Barclay, W., Deeks, J. J., & Lalvani, A. (2013) · Nature Medicine · doi:10.1038/nm.3350 · Cited by 862 · see citing works
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795 · see citing works
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706 · see citing works
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works
Self-citationEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651 · see citing works
Self-citationEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651 · see citing works
Self-citationter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S.-W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 599 · see citing works
Neutralizing Activity of BNT162b2-Elicited Serum
Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537 · see citing works
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., et al. (2021) · Science · doi:10.1126/science.abg6105 · Cited by 515 · see citing works
Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01179-4 · Cited by 315 · see citing works
Self-citationCaly, L., Druce, J. D., Roberts, J., Bond, K. A., Tran, T., Kostecki, R., Yoga, Y., Naughton, W., Taiaroa, G., Seemann, T., et al. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50569 · Cited by 305 · see citing works
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n296 · Cited by 235 · see citing works
SARS-CoV-2 evolution and vaccines: cause for concern?
Williams, T., & Burgers, W. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00075-8 · Cited by 163 · see citing works
MAIT cell activation augments adenovirus vector vaccine immunogenicity
Provine, N. M., Amini, A., Garner, L. C., Spencer, A. J., Dold, C., Hutchings, C. L., Silva-Reyes, L., FitzPatrick, M. E. B., Chinnakannan, S. K., Oguti, B., et al. (2021) · Science · doi:10.1126/science.aax8819 · Cited by 130 · see citing works
Self-citationOgbe, A., Kronsteiner, B., Skelly, D., Pace, M. J., Brown, A., Adland, E., Adair, K., Akhter, H. D., Ali, M., Ali, S.-E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21856-3 · Cited by 121 · see citing works
Self-citationModelling changes in glutathione homeostasis as a function of quinone redox metabolism
Kelly, R. A., Leedale, J., Calleja, D., Enoch, S. J., Harrell, A., Chadwick, A. E., & Webb, S. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-42799-2 · Cited by 99 · see citing works
Discrete SARS-CoV-2 antibody titers track with functional humoral stability
Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo, C., Gorman, M. J., Zhu, A. L., Kang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21336-8 · Cited by 82 · see citing works
Modulating Antibody Functionality in Infectious Disease and Vaccination
Gunn, B. M., & Alter, G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.09.002 · Cited by 80 · see citing works
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
Huang, K.-Y. A., Tan, T., Chen, T.-H., Huang, C.-G., Harvey, R., Hussain, S., Chen, C.-P., Harding, A. C., Gilbert-Jaramillo, J., Liu, X., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009352 · Cited by 64 · see citing works
Self-citationCorrelates of Vaccine-Induced Protection against SARS-CoV-2
Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 53 · see citing works
Huang, K.-Y. A., Rijal, P., Jiang, H., Wang, B., Schimanski, L. M., Dong, T., Liu, Y.-M., Chang, P., Iqbal, M., Wang, M.-C., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0303-7 · Cited by 50 · see citing works
Self-citationGooch, K. E., Marriott, A. C., Ryan, K. A., Yeates, P., Slack, G. S., Brown, P. J., Fothergill, R., Whittaker, C. J., & Carroll, M. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-38885-0 · Cited by 23 · see citing works
Self-citationMOCCASIN: a method for correcting for known and unknown confounders in RNA splicing analysis
Slaff, B., Radens, C. M., Jewell, P. D., Jha, A., Lahens, N. F., Grant, G. R., Thomas‐Tikhonenko, A., Lynch, K. W., & Barash, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-23608-9 · Cited by 23 · see citing works
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n124 · Cited by 23 · see citing works
Gooch, K. E., Smith, T. R. F., Salguero, F. J., Fotheringham, S. A., Watson, R. J., Dennis, M. J., Handley, A., Humphries, H. E., Longet, S., Tipton, T., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.057 · Cited by 18 · see citing works
Self-citationArunachalam, P. S., Walls, A. C., Golden, N., Atyeo, C. G., Fischinger, S., Li, C., Aye, P. P., Navarro, M. J., Lai, L., Edara, V. V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.10.430696 · Cited by 15 · see citing works
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1933594 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353 · see citing works
Self-citationThe T cell immune response against SARS-CoV-2
Moss, P. A. H. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,205 · see citing works
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911 · see citing works
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706 · see citing works
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works
Self-citationEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651 · see citing works
Self-citationAntibody evasion by the P.1 strain of SARS-CoV-2
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583 · see citing works
Self-citationNeutralizing Activity of BNT162b2-Elicited Serum
Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537 · see citing works
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
García-Beltrán, W. F., Lam, E. C., Denis, K. S., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J. E., Pavlovic, M., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.006 · Cited by 446 · see citing works
Self-citationRapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine
Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., Csernalabics, B., Lang-Meli, J., Janowska, I., Staniek, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03841-4 · Cited by 391 · see citing works
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu‐Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01464-w · Cited by 340 · see citing works
The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic
Otto, S. P., Day, T., Arino, J., Colijn, C., Dushoff, J. G., Li, M., Mechai, S., Domselaar, G. V., Wu, J., Earn, D. J. D., et al. (2021) · Current Biology · doi:10.1016/j.cub.2021.06.049 · Cited by 316 · see citing works
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.10.011 · Cited by 322 · see citing works
Self-citationAssociation Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination
Edelman, A., Boniface, E. R., Benhar, E., Han, L., Matteson, K. A., Favaro, C., Pearson, J. T., & Darney, B. G. (2022) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004695 · Cited by 281 · see citing works
Zeng, B., Gao, L., Zhou, Q., Yu, K., & Sun, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02397-y · Cited by 267 · see citing works
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 190 · see citing works
T Cell Responses to SARS-CoV-2
Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 181 · see citing works
Angyal, A., Longet, S., Moore, S. C., Payne, R., Harding, A. C., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00275-5 · Cited by 176 · see citing works
Self-citationBarnes, E. J., Goodyear, C. S., Willicombe, M. K., Gaskell, C., Siebert, S., de Silva, T. I., Murray, S. M., Rea, D. W., Snowden, J. A., Carroll, M. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02414-4 · Cited by 132 · see citing works
Self-citationRobust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Liu, Y., Zeng, Q., Deng, C., Li, M., Li, L., Liu, D., Liu, M., Ruan, X., Mei, J., Mo, R., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00373-7 · Cited by 122 · see citing works
Andre, M., Lau, L. S., Pokharel, M. D., Ramelow, J., Owens, F., Souchak, J., Akkaoui, J., Ales, E., Brown, H. H., Shil, R. K., et al. (2023) · Biology · doi:10.3390/biology12091267 · Cited by 108 · see citing works
Self-citationRETRACTED: SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Ng, K. W., Faulkner, N., Finsterbusch, K., Wu, M., Harvey, R., Hussain, S., Greco, M., Liu, Y., Kjær, S., Swanton, C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3715 · Cited by 95 · see citing works
RetractedNeidleman, J. A., Luo, X., McGregor, M. M., Xie, G., Murray, V., Greene, W. C., Lee, S. A., & Roan, N. R. (2021) · eLife · doi:10.7554/elife.72619 · Cited by 88 · see citing works
Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 85 · see citing works
Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz‐Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., & Pałgan, K. (2021) · Cells · doi:10.3390/cells10081952 · Cited by 82 · see citing works
Menstrual abnormalities after COVID-19 vaccines: A systematic review
Nazir, M., Asghar, S., Rathore, M. A., Shahzad, A., Shahid, A., Khan, A. A., Malik, A. A., Fakhar, T., Kausar, H., & Malik, J. (2022) · Vacunas · doi:10.1016/j.vacun.2022.07.001 · Cited by 93 · see citing works
Reinscheid, M., Luxenburger, H., Karl, V., Graeser, A., Giese, S., Ciminski, K., Reeg, D. B., Oberhardt, V., Roehlen, N., Lang‐Meli, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32324-x · Cited by 79 · see citing works
PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection
Xu, D., Jiang, W., Wu, L., Gaudet, R. G., Park, E., Su, M., Cheppali, S. K., Cheemarla, N. R., Kumar, P., Uchil, P. D., et al. (2023) · Nature · doi:10.1038/s41586-023-06322-y · Cited by 76 · see citing works
Brown, J. C., Goldhill, D. H., Zhou, J., Peacock, T. P., Frise, R., Goonawardane, N., Baillon, L., Kugathasan, R., Pinto, A., McKay, P. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.24.432576 · Cited by 68 · see citing works
Wang, S., Mortazavi, J., Hart, J. E., Hankins, J. A., Katuska, L. M., Farland, L. V., Gaskins, A. J., Wang, Y., Tamimi, R. M., Terry, K. L., et al. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.003 · Cited by 73 · see citing works
Lumley, S., Rodger, G., Constantinides, B., Sanderson, N. D., Chau, K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab608 · Cited by 70 · see citing works
Self-citationKaraba, A. H., Johnston, T. S., Aytenfisu, T. Y., Akinde, O., Eby, Y. J., Ruff, J. E., Abedon, A. T., Alejo, J. L., Blankson, J. N., Cox, A. L., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004140 · Cited by 71 · see citing works
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64 · see citing works
T cell immune memory after covid-19 and vaccination
Wang, L., Nicols, A. R., Turtle, L. C. W., Richter, A. G., Duncan, C. J. A., Dunachie, S. J., Klenerman, P., & Payne, R. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000468 · Cited by 61 · see citing works
Self-citationAlexander, J. L., Mullish, B. H., Danckert, N. P., Liu, Z., Olbei, M. L., Saifuddin, A., Torkizadeh, M., Ibraheim, H., Blanco, J. M., Roberts, L. A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104430 · Cited by 57 · see citing works
Faulkner, N., Ng, K. W., Wu, M. Y., Harvey, R., Margaritis, M., Paraskevopoulou, S., Houlihan, C., Hussain, S., Greco, M., Bolland, W., et al. (2021) · eLife · doi:10.7554/elife.69317 · Cited by 52 · see citing works
Self-citationCrowley, A. R., Natarajan, H., Hederman, A. P., Bobak, C. A., Weiner, J. A., Wieland-Alter, W., Lee, J., Bloch, E. M., Tobian, A. A. R., Redd, A. D., et al. (2022) · eLife · doi:10.7554/elife.75228 · Cited by 49 · see citing works
Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva-Reyes, L., Meardon, N., Faustini, S. E., et al. (2023) · Med · doi:10.1016/j.medj.2023.02.004 · Cited by 53 · see citing works
Self-citationCOVID‑19 vaccination and IgG and IgA antibody dynamics in healthcare workers
Zurac, S., Nichita, L., Mateescu, B. R., Mogodici, C., Bastian, A. E., Popp, C. G., Cioplea, M. D., Socoliu, C., Constantin, C., & Neagu, M. T. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12217 · Cited by 48 · see citing works
Lumley, S., Rodger, G., Constantinides, B., Sanderson, N., Chau, K. K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21253218 · Cited by 48 · see citing works
Self-citationRevisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here
Halperin, D. T., Hearst, N., Hodgins, S., Bailey, R. C., Klausner, J. D., Jackson, H., Wamai, R. G., Ladapo, J. A., Over, M., Baral, S., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12082-z · Cited by 45 · see citing works
Mazzoni, A., Vanni, A., Spinicci, M., Capone, M., Lamacchia, G., Salvati, L., Coppi, M., Antonelli, A., Carnasciali, A., Farahvachi, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801431 · Cited by 44 · see citing works
Verhagen, J., van der Meijden, E. D., Lang, V., Kremer, A. E., Völkl, S., Mackensen, A., Aigner, M., & Kremer, A. N. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13627 · Cited by 42 · see citing works
Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
Mancuso, M., Eikenberry, S. E., & Gumel, A. B. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.08.008 · Cited by 42 · see citing works
The past, current and future epidemiological dynamic of SARS-CoV-2
Balloux, F., Tan, C. C. S., Swadling, L., Richard, D., Jenner, C., Maini, M. K., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 37 · see citing works
Zani, A., Caccuri, F., Messali, S., Bonfanti, C., & Caruso, A. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1940305 · Cited by 40 · see citing works
Gonçalves, J., Juliano, A. M., Charepe, N., Alenquer, M., Athayde, D., Ferreira, F., Archer, M., Amorim, M. J., Serrano, F., & Soares, H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100468 · Cited by 41 · see citing works
Pieren, D. K. J., Kuguel, S. G., Rosado, J., Robles, A. G., Rey-Cano, J., Mancebo-Pérez, C., Esperalba, J., Falcó, V., Buzón, M. J., & Genescà, M. (2023) · Nature Communications · doi:10.1038/s41467-023-37559-w · Cited by 39 · see citing works
Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac404 · Cited by 39 · see citing works
Mazzoni, A., Vanni, A., Spinicci, M., Lamacchia, G., Kiros, S. T., Rocca, A., Capone, M., Lauria, N. D., Salvati, L., Carnasciali, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157990 · Cited by 38 · see citing works
Gerber, P. P., Duncan, L. M., Greenwood, E. J. D., Marelli, S., Naamati, A., Teixeira-Silva, A., Crozier, T. W. M., Gabaev, I., Zhan, J. R., Mulroney, T. E., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010265 · Cited by 35 · see citing works
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomić, A., Skelly, D., Ogbe, A., O’Connor, D., Pace, M. J., Adland, E., Alexander, F., Ali, M., Allott, K., Ansari, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28898-1 · Cited by 35 · see citing works
Self-citationMazzoni, A., Vanni, A., Spinicci, M., Lamacchia, G., Kiros, S. T., Rocca, A., Capone, M., Lauria, N. D., Salvati, L., Carnasciali, A., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 36 · see citing works
Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
Paniskaki, K., Anft, M., Meister, T. L., Marheinecke, C. S., Pfaender, S., Skrzypczyk, S., Seibert, F. S., Thieme, C. J., Konik, M., Dolff, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816220 · Cited by 33 · see citing works
Immune response against SARS-CoV-2 variants: the role of neutralization assays
Chmielewska, A., Czarnota, A., Bieńkowska-Szewczyk, K., & Grzyb, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00404-6 · Cited by 33 · see citing works
Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination
Armistead, B., Jiang, Y., Carlson, M., Ford, E. S., Jani, S., Houck, J., Wu, X., Jing, L., Pecor, T., Kachikis, A. B., et al. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.01.003 · Cited by 33 · see citing works
Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults
Semelka, C., DeWitt, M., Blevins, M. W., Holbrook, B. C., Sanders, J. W., & Alexander‐Miller, M. A. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00327-x · Cited by 33 · see citing works
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Yuan, Y., Zhang, X., Chen, R., Li, Y., Wu, B., Li, R., Zou, F., Ma, X., Wang, X., Chen, Q., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110256 · Cited by 31 · see citing works
Aoki, H., Kitabatake, M., Abe, H., Xu, P., Tsunoda, M., Shichino, S., Hara, A., Ouji-Sageshima, N., Motozono, C., Ito, T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113887 · Cited by 28 · see citing works
COVID-19 vaccination and menstrual disorders among women: Findings from a meta-analysis study
Kadri, H. M. A., Sudairy, A. A. A., Alangari, A. S., Al-Khateeb, B. F., & El‐Metwally, A. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.02.019 · Cited by 29 · see citing works
Kim, S. J., Yao, Z., Marsh, M., Eckert, D. M., Kay, M. S., Lyakisheva, A., Pasic, M. D., Bansal, A., Birnboim, C., Jha, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31300-9 · Cited by 27 · see citing works
Singer, S. R., Angulo, F. J., Swerdlow, D. L., McLaughlin, J. M., Hazan, I., Ginish, N., Anis, E., Mendelson, E., Mor, O., Zuckerman, N. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101190 · Cited by 30 · see citing works
Bai, J., Chiba, A., Murayama, G., Kuga, T., Tamura, N., & Miyake, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.786586 · Cited by 27 · see citing works
Keppler‐Hafkemeyer, A., Greil, C., Wratil, P. R., Shoumariyeh, K., Stern, M., Hafkemeyer, A., Ashok, D., Hollaus, A., Lupoli, G., Priller, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00502-x · Cited by 27 · see citing works
Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
Tang, Q., Owens, R. J., & Naismith, J. H. (2021) · Viruses · doi:10.3390/v13112214 · Cited by 26 · see citing works
May, D., Rubin, B. E., Dalai, S. C., Patel, K. J., Shafiani, S., Elyanow, R., Noakes, M. T., Snyder, T. M., & Robins, H. S. (2021) · medRxiv · doi:10.1101/2021.12.20.21267877 · Cited by 26 · see citing works
Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines
Yaqinuddin, A., Shafqat, A., Kashir, J., & AlKattan, K. M. (2021) · Vaccines · doi:10.3390/vaccines9080914 · Cited by 25 · see citing works
Paramithiotis, E., Sugden, S., Papp, E., Bonhomme, M., Chermak, T., Crawford, S. Y., Demetriades, S. Z., Galdos, G., Lambert, B. L., Mattison, J. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880784 · Cited by 24 · see citing works
Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Saresella, M., Piancone, F., Marventano, I., Hernis, A., Trabattoni, D., Invernizzi, M., Rosa, F. L., & Clerici, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947320 · Cited by 24 · see citing works
Caldera, F., Farraye, F. A., Necela, B. M., Cogen, D., Saha, S., Wald, A. M., Daoud, N. D., Chun, K., Grimes, I. C., Lutz, M. K., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac193 · Cited by 23 · see citing works
Longet, S., Hargreaves, A., Healy, S., Brown, R. L., Hornsby, H. R., Meardon, N., Tipton, T., Barnes, E. J., Dunachie, S. J., Duncan, C. J. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953949 · Cited by 20 · see citing works
Self-citationFiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · doi:10.31219/osf.io/z4x7t · Cited by 22 · see citing works
COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study
Wesselink, A. K., Lovett, S. M., Weinberg, J., Geller, R. J., Wang, T. R., Regan, A. K., Willis, M. D., Perkins, R. B., Yland, J. J., Koenig, M. R., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.012 · Cited by 21 · see citing works
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
Ng, K. W., Faulkner, N., Wrobel, A. G., Gamblin, S. J., & Kassiotis, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101507 · Cited by 19 · see citing works
Mellors, J., Tipton, T., Fehling, S. K., Boré, J. A., Koundouno, F. R., Hall, Y., Hudson, J., Alexander, F., Longet, S., Taylor, S. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857481 · Cited by 20 · see citing works
Self-citationChevaisrakul, P., Lumjiaktase, P., Kietdumrongwong, P., Chuatrisorn, I., Chatsangjaroen, P., & Phanuphak, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-28101-5 · Cited by 19 · see citing works
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio
Vergori, A., Tavelli, A., Matusali, G., Azzini, A. M., Augello, M., Mazzotta, V., Pellicanò, G. F., Costantini, A., Cascio, A., VITO, A. D., et al. (2023) · Vaccines · doi:10.3390/vaccines11111664 · Cited by 19 · see citing works
Lien, C.-E., Kuo, T., Lin, Y., Lian, W., Lin, M., Liu, L. T.-C., Cheng, J., Chou, Y., & Chen, C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab711 · Cited by 18 · see citing works
Minakshi, R., Rahman, S., Ayaggari, A., Dutta, D., & Shankar, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906091 · Cited by 18 · see citing works
Fernández-Ciriza, L., González, Á., del Pozo, J. L., Fernández‐Montero, A., Carmona-Torre, F., Carlos, S., Sarasa, M. D. M., & Reina, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-19537-2 · Cited by 18 · see citing works
Fujii, S., Yamasaki, S., Iyoda, T., & Shimizu, K. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00239-1 · Cited by 17 · see citing works
Matar, S. G., Nourelden, A. Z., Assar, A., Bahbah, E. I., Alfryjat, A. M., Hasabo, E. A., Matar, S. A., Bishtawi, S. N., Alhoubani, M., Yahia, A. B., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13088 · Cited by 22 · see citing works
Johnson, S. A., Phillips, E., Adele, S., Longet, S., Malone, T., Mason, C. J., Stafford, L., Jämsén, A., Gardiner, S., Deeks, A. S., et al. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad027 · Cited by 18 · see citing works
Self-citationDutta, K., Elmezayen, A. D., Al-Obaidi, A., Zhu, W., Morozova, O. V., Shityakov, S., & Khalifa, I. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131113 · Cited by 18 · see citing works
Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago
Qiang, M., Ma, P., Li, Y., Liu, H., Harding, A. C., Min, C., Wang, F., Liu, L., Yuan, M., Ji, Q., et al. (2021) · Advancement of science · doi:10.1002/advs.202102181 · Cited by 12 · see citing works
Self-citationT cells in SARS-CoV-2 infection and vaccination
Young, A. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221115011 · Cited by 16 · see citing works
Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
Conway, S. R., Keller, M. D., & Bollard, C. M. (2022) · Blood · doi:10.1182/blood.2021012249 · Cited by 17 · see citing works
Richardson, J. R., Götz, R., Mayr, V., Lohse, M. J., Holthoff, H., & Ungerer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266701 · Cited by 16 · see citing works
SARS-CoV-2 infection and female reproductive health: A narrative review
Maher, M., & Owens, L. A. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101760 · Cited by 17 · see citing works
The molecular reach of antibodies crucially underpins their viral neutralisation capacity
Huhn, A. G., Nissley, D. A., Wilson, D. B., Kutuzov, M. A., Donat, R. F., Tan, T. K., Zhang, Y., Barton, M. I., Liu, C., Dejnirattisai, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54916-5 · Cited by 16 · see citing works
Self-citationJubishi, D., Okamoto, K., Hamada, K., Ishii, T., Hashimoto, H., Shinohara, T., Yamashita, M., Wakimoto, Y., Otani, A., Hisasue, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2048559 · Cited by 16 · see citing works
Multipolymer microsphere delivery of SARS-CoV-2 antigens
Shahjin, F., Patel, M., Machhi, J., Cohen, J. D., Nayan, M. U., Yeapuri, P., Zhang, C., Waight, E. M., Hasan, M., Abdelmoaty, M. M., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.043 · Cited by 15 · see citing works
SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
Pitiriga, V. C., Papamentzelopoulou, M., Konstantinakou, K. E., Theodoridou, K., Vasileiou, I. V., & Tsakris, A. (2023) · Vaccines · doi:10.3390/vaccines11071186 · Cited by 16 · see citing works
Yang, Y., Wang, B., Li, W., Cai, H.-L., Qian, Q.-Y., Yu, Q. P., Shi, F., Bosch, B., & Huang, Y. (2024) · Journal of Virology · doi:10.1128/jvi.00139-24 · Cited by 15 · see citing works
Tartaro, D. L., Paolini, A., Mattioli, M., Swatler, J., Neroni, A., Borella, R., Santacroce, E., Nella, A. D., Gozzi, L., Busani, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123724 · Cited by 13 · see citing works
Xu, Z., Song, J. H., Zhang, H., Wei, Z., Wei, D., Guangyu, Y., Jacques Demongeot, A., & Zeng, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-74221-x · Cited by 15 · see citing works
The Impact of COVID-19 on Menstrual Cycle in Women
Błażejewski, G., & Witkoś, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154991 · Cited by 15 · see citing works
Jay, C., Adland, E., Csala, A., Lim, N. T. Y., Longet, S., Ogbe, A., Ratcliff, J., Sampson, O. L., Thompson, C., Turtle, L. C. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248630 · Cited by 13 · see citing works
Self-citationThe Influence of Cross-Reactive T Cells in COVID-19
Eggenhuizen, P. J., & Ooi, J. D. (2024) · Biomedicines · doi:10.3390/biomedicines12030564 · Cited by 14 · see citing works
Kovalchik, K. A., Hamelin, D. J., Kubiniok, P., Bourdin, B., Mostefai, F., Poujol, R., Paré, B., Simpson, S. M., Sidney, J., Bonneil, É., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54734-9 · Cited by 13 · see citing works
- Authors
- Skelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., Tipton, T., Stafford, L., Johnson, S. A., Amini, A., Group, O. C., Kit Tan, T., Schimanski, L., Huang, K.-Y. A., Rijal, P., Group, P. S., Group, C.-C., Frater, J., Goulder, P., Conlon, C. P., Jeffery, K., Dold, C., Pollard, A. J., Sigal, A., de Oliveira, T., Townsend, A. R., Klenerman, P., Dunachie, S. J., Barnes, E., Carroll, M. W., & James, W. S.
- Affiliations
- University of Oxford (GB)
- Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
- Public Health England, Porton Down, UK
- Centre for Human Genetics (GB)
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tao Yuan General Hospital (TW)
- KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa, 4001
- Corresponding author
- James, William S.
- ORCID
- Skelly, Donal T.
- Harding, Adam C.
- Gilbert-Jaramillo, Javier
- Knight, Michael L.
- Longet, Stephanie
- Anthony Brown
- Adele, Sandra
- Brown, Helen
- Tom Tipton
- Stafford, Lizzie
- Johnson, Síle A.
- Amini, Ali
- Kit Tan, Tiong
- Huang, Kuan-Ying A.
- Rijal, Pramila
- Frater, John
- Goulder, Philip
- Conlon, Christopher P.
- Jeffery, Katie
- Dold, Christina
- Pollard, Andrew J.
- Sigal, Alex
- de Oliveira, Tulio
- Townsend, Alain R.
- Klenerman, Paul
- Dunachie, Susanna J .
- Barnes, Eleanor
- Carroll, Miles W.
- James, William S.
- Venue
- Nature Communications
- Published
- 2021-03-29
- Volume
- 12
- Issue
- 1
- Pages
- 5061-5061
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8371089
- OpenAlex
- W3193567675
- Cited by
- 216
- References
- 50
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 21 · 2023: 49 · 2022: 75 · 2021: 55
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Meso Scale Diagnostics
- Wellcome Trust (216417/Z/19/Z, 204721/Z/16/Z, WT 109965MA, 110,110z/15/Z, 211153/Z/18/Z, 109965/Z/15/Z)
- UK Research and Innovation (NIHR200907, MR/V027859/1)
- National Institute for Health Research Health Protection Research Unit (NIHR200907)
- National Institute for Health and Care Research (NIHR-INF-0067, CL-2018-13-007, NIHR-INF-1867, 10980107, U19 I082360, ACF-2019-13-003, DHCS/04/G121/68, COVID-19, ACF-2018-13-005, NIHR300791, MR/V027859/1, WT109965MA, COV19-RECPLA, NF-SI-0515-10005, CL-2020-13-002, NIHR200907, CL-2013-13-003, NF-SI-0617-10139)
- British Heart Foundation (RE/18/3/34214)
- Department of Health and Social Care (COVID-19)
- University of Oxford (RE/18/3/34214, NIHR200907)
- University of New South Wales
- Public Health England
- Huo Family Foundation
- Hamilton Health Sciences Foundation
- UK Coronavirus Immunology Consortium
- National Institutes of Health (WT109965MA, U19 I082360, COVID-19)
- Medical Research Council (MR/V027859/1, 75F40120C00085, MR/L006588/1, COVID-19)
- Biotechnology and Biological Sciences Research Council
- NIHR Oxford Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- SARS-CoV-2, COVID-19 vaccines, variants of concern, Beta variant, Alpha variant, neutralizing antibodies, T cell response, booster vaccination, natural infection, conserved epitopes, vaccine efficacy
- MeSH terms
- Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Animals, Antibodies, Monoclonal, Antibodies, Viral, Epitopes, Carrier Proteins, Humans, Immunity, T-Lymphocytes, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
